Concizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Tissue factor pathway inhibitor |
| Clinical data | |
| Trade names | Alhemo |
| Other names | concizumab-mtci |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625040 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | Antihemorrhagic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H10004N1712O2046S46 |
| Molar mass | 145887.81 g·mol−1 |
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. It is an anti-tissue factor pathway inhibitor.
The most common adverse reactions include injection site reactions and hives (urticaria). Concizumab can cause thromboembolic events, hypersensitivity, and increased laboratory values of fibrin D dimer and prothrombin fragment 1+2.
Concizumab was approved for medical use in Canada in March 2023, in Australia in July 2023, in the European Union in December 2024, and the United States in December 2024.